NKF 2010 Spring Meetings Coverage


Follow our archived coverage from the 2010 National Kidney Foundation Spring Clinical Meetings in Orlando, Fla., including our four sections below that were updated daily.



Study Finds No Link Between FGF-23 and Dietary Phosphorus

LAS VEGAS—Fibroblast growth factor 23 (FGF-23) is not significantly associated with dietary phosphorus or urinary phosphorus excretion, researchers reported at the National Kidney Foundation's Spring Clinical Meetings.

Study Examines Impact of Ergocalciferol on Markers of Bone and Mineral Metabolism

Study Examines Impact of Ergocalciferol on Markers of Bone and Mineral Metabolism

Weekly (50,000 units) and monthly doses (50,000 units) of ergocalciferol treatment does not significantly impact markers of mineral metabolism (MM) in chronic hemodialysis (HD) patients, a study suggests.

Thrice-Weekly Post-Dialysis Cinacalcet A Viable Option

New approach may ease problems with noncompliance, according to researchers.

SHPT Treatment May Have CAC Benefit

SHPT Treatment May Have CAC Benefit

Cinacalcet plus low-dose vitamin D for secondary hyperparathyroidism yielded encouraging results

Death Risk Is Lower With Peritoneal Dialysis

Compared with incident hemodialysis (HD) patients, incident peritoneal dialysis (PD) patients, especially non-diabetics, show a robust and consistent survival advantage for up to five years.

Better Preparation Before Dialysis Improves Survival

Patients with renal disease who are well prepared to start dialysis are significantly more likely to survive their first year of treatment, according to a study presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.

Repeat Injections of Ferumoxytol Well Tolerated

Ferumoxytol, a novel IV iron replacement therapy for CKD patients with iron deficiency anemia, is well tolerated regardless of the number of injections or interval between injections.

Polycystic Kidney Disease Affects PTH-Related Mortality

Very high and very low parathyroid hormone (PTH) levels are associated with the highest mortality rates in hemodialysis (HD) patients.

Catheters Are the Most Common Vascular Access Type after Renal Allograft Failure

Central venous catheters are the most prevalent access type in patients who initiated hemodialysis (HD) following a failed renal transplant.

Paricalcitol Improves Survival Regardless of Baseline iPTH Levels

Use of paricalcitol for hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) is associated with a significant improvement in survival independent of baseline levels of intact parathyroid hormone (iPTH) compared with patients who have untreated SHPT.

Phosphate Binder May Reduce the Number of Hospitalization Days

Using sevelamer instead of calcium-based binders (CBBs) to treat hyperphosphatemia in dialysis patients can significantly decrease the number of days of hospitalization.

Iron Deficiency Common in CKD Patients

Researchers who studied a group of non-dialysis CKD patients found that about one quarter of them suffered from iron deficiency anemia.

Cinacalcet Plus Low-Dose Vitamin D May Slow CAC Progression

Cinacalcet plus low-dose vitamin D therapy may improve biochemical control of secondary hyperparathyroidism (SHPT) and attenuate progression of coronary artery calcification (CAC) compared with flexible vitamin D therapy alone in hemodialysis (HD) patients.

Sevelamer Carbonate May Impair Calcitriol Bioavailability

Sevelamer carbonate significantly decreases the bioavailability of oral calcitriol when the two drugs are administered together, but lanthanum carbonate does not, show data presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.

Fluid Intake with Phosphate Binders Quantified

The daily fluid intake with phosphate binder (PB) pills accounts for a significant portion of the daily fluid restriction in hemodialysis (HD) patients, suggest data presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.

Sign Up for Free e-newsletters